Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Microbix Biosystems Inc. T.MBX

Alternate Symbol(s):  MBXBF

Microbix develops proprietary biological technology solutions for human health and well-being, with about 90 skilled employees and sales growing from a base of over $1 million per month. It makes a wide range of critical biological materials for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs™) that support clinical lab proficiency testing, assay development and validation, or clinical lab workflows.


TSX:MBX - Post by User

Bullboard Posts
Comment by zenvestingon Jul 28, 2014 9:27am
194 Views
Post# 22786587

RE:Zenvesting.........

RE:Zenvesting.........I agree fundamentally on everything you say about the strength of the case Microbix has; but think your royalty assumption might be a bit generous.  I'm not an expert in the field, but from what I've seen in the past, a 3-5% royalty seams to be the range for a non-exclusive, non-participating patantee in the biomedical field.  

Here you will see a dose of Agriflu is sold for about $13:
https://www.cdc.gov/vaccines/programs/vfc/awardees/vaccine-management/price-list/2011/2011-01-01.html

So applying the high side of that royalty range at 5% to the $13/dose translates to $0.65 per dose.  

As the saying goes, "Hope for the best, but be prepared for the worst", I personally believe we have a winnable case, but think the damages will come in more in the $50M range in Texas....which is still a huge windfall for a stock currently valued at about $45 Million! (accounting for full conversion of all debuntures).
Bullboard Posts